Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 43; no. 8; p. 651
• Main Authors: Song, F M, Hu, Y X, Zhang, M M, Wu, W W, Xu, H J, Zhang, H S, Huang, H, Wei, G Q
• Format: Journal Article
• Language: Chinese
• Published: China 14.08.2022
• Subjects: Antigens, CD19; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive - adverse effects; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy; Receptors, Chimeric Antigen - therapeutic use; T-Lymphocytes; Refractory; Humanized; Chimeric antigen receptor T cell; Acute lymphoblastic leukemia acute; Relapsed
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2022.08.006

This study aimed to evaluate the safety and efficacy of humanized CD19-targeted chimeric antigen receptor T-cell (CAR-T) in patients with relapsed/refractory acute B cell lymphoblastic leukemia (R/R B-ALL) . The clinical data of 41 patients with R/R B-ALL treated with humanized CD19-targeted CAR-T cells in the First Affiliated Hospital of Zhejiang University School of Medicine from February 2020 to July 2021 were analyzed. Cytokine release syndrome occurred in all patients, and 63.4% (26/41) were grades 1-2. Immune effector cell-associated neurotoxicity syndrome developed in three patients. On median day 15 (9-47) , the complete remission rate was 95.1% (39/41) , of which 38 patients tested negative for bone marrow minimal residual disease detected by flow cytometry. Among the 39 patients with complete remission, 17 patients did not receive further treatment, and 70.6% (12/17) remained in remission at the end of follow-up, with a progression-free survival of 11.6 months of the two patients with the earliest i